TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiativesNEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG ...

TG Therapeutics, Inc.: TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit ...
Health.com

What Causes a Gastrointestinal (GI) Bleed?

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...